AMGEN INC (AMG.DE) Stock Overview
FRA:AMG - US0311621009 - Common Stock
AMG.DE Key Statistics, Chart & Performance
The current stock price of AMG.DE is 257.4 EUR. In the past month the price increased by 4.85%. In the past year, price decreased by -12.83%.
AMG.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 19.98 | 321.13B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.11 | 124.65B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.62 | 88.26B | ||
| ARGX.BR | ARGENX SE | 77.63 | 35.25B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 23.01B | ||
| IDP.DE | BIOGEN INC | 8.73 | 17.60B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.98B | ||
| 0QF.DE | MODERNA INC | N/A | 8.77B | ||
| ABVX.PA | ABIVAX SA | N/A | 4.96B | ||
| 1VKTX.MI | VIKING THERAPEUTICS INC | N/A | 2.47B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.82B | ||
| AZT.OL | ARCTICZYMES TECHNOLOGIES ASA | 1460 | 1.49B |
Related stock screener links
About AMG.DE
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA US
Employees: 28000
Phone: 18054471000
AMGEN INC / AMG.DE FAQ
What is the stock price of AMGEN INC today?
The current stock price of AMG.DE is 257.4 EUR. The price increased by 1.62% in the last trading session.
What is the ticker symbol for AMGEN INC stock?
The exchange symbol of AMGEN INC is AMG and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is AMG.DE stock listed?
AMG.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for AMGEN INC stock?
39 analysts have analysed AMG.DE and the average price target is 273.75 EUR. This implies a price increase of 6.35% is expected in the next year compared to the current price of 257.4. Check the AMGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMGEN INC worth?
AMGEN INC (AMG.DE) has a market capitalization of 138.41B EUR. This makes AMG.DE a Large Cap stock.
How many employees does AMGEN INC have?
AMGEN INC (AMG.DE) currently has 28000 employees.
What are the support and resistance levels for AMGEN INC (AMG.DE) stock?
AMGEN INC (AMG.DE) has a support level at 256.31 and a resistance level at 260.26. Check the full technical report for a detailed analysis of AMG.DE support and resistance levels.
Is AMGEN INC (AMG.DE) expected to grow?
The Revenue of AMGEN INC (AMG.DE) is expected to grow by 6.58% in the next year. Check the estimates tab for more information on the AMG.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMGEN INC (AMG.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMG.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMG.DE, evaluating the profitability, health, valuation and growth aspects
- AMGEN INC (AMG.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMGEN INC (AMG.DE) Sales and EPS estimates to see what analysts future expectations are.
- AMGEN INC (AMG.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMGEN INC (AMG.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMGEN INC (AMG.DE) Stock Chart to make your own analysis
- AMGEN INC (AMG.DE) Latest news and press-releases to stay up to date.
Does AMGEN INC (AMG.DE) stock pay dividends?
AMGEN INC (AMG.DE) has a dividend yield of 3.28%. The yearly dividend amount is currently 7.71. Check the full fundamental report for a detailed analysis of AMG.DE dividend history, reliability and sustainability.
When does AMGEN INC (AMG.DE) report earnings?
AMGEN INC (AMG.DE) will report earnings on 2025-10-28, before the market open.
What is the Price/Earnings (PE) ratio of AMGEN INC (AMG.DE)?
The PE ratio for AMGEN INC (AMG.DE) is 13.74. This is based on the reported non-GAAP earnings per share of 18.74 and the current share price of 257.4 EUR. Check the full fundamental report for a full analysis of the valuation metrics for AMG.DE.
AMG.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AMG.DE. When comparing the yearly performance of all stocks, AMG.DE is a bad performer in the overall market: 79.37% of all stocks are doing better.
AMG.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMG.DE. AMG.DE has an excellent profitability rating, but there are concerns on its financial health.
AMG.DE Financial Highlights
Over the last trailing twelve months AMG.DE reported a non-GAAP Earnings per Share(EPS) of 18.74. The EPS increased by 17.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.96% | ||
| ROA | 7.53% | ||
| ROE | 89.11% | ||
| Debt/Equity | 7.24 |
AMG.DE Forecast & Estimates
39 analysts have analysed AMG.DE and the average price target is 273.75 EUR. This implies a price increase of 6.35% is expected in the next year compared to the current price of 257.4.
For the next year, analysts expect an EPS growth of 7.47% and a revenue growth 6.58% for AMG.DE